Imipramine, methylphenidate and valproic acid-related EPS in a child: A case report [1]

International Journal of Neuropsychopharmacology

Volumn 10, Issue 5, 2007, Pages 705-707

  Tahiroglu, Aysegul Yolga ^a   Avci, Ayse ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE; IMIPRAMINE; METHYLPHENIDATE; VALPROIC ACID;

AGGRESSION; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CASE REPORT; DEPRESSION; EXTRAPYRAMIDAL SYMPTOM; EYE PAIN; FEMALE; HUMAN; LETTER; OCULOGYRIC CRISIS; PRIORITY JOURNAL; SCHOOL CHILD;

BASAL GANGLIA DISEASES; CHILD; FEMALE; HUMANS; IMIPRAMINE; METHYLPHENIDATE; VALPROIC ACID;

EID: 34948881713     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145707007791     Document Type: Letter

References (26)

1. Alvarez-Gomez MJ, Vaamonde J, Narbona J, Barao M, Barona P, Brannan T (1993). Parkinsonian syndrome in childhood after sodium valproate administration. Clinical Neuropharmacology 16, 451-455.
2. Biederman JM, Faraone SV (1999). Futher evidence of a bidirectional overlap between juvenile mania and conduct disorder in children. Journal of the American Academy of Child and Adolescent Psychiatry 38, 468-476.
3. Caley CF (1997). Extrapyramidal reaction and selective serotonin reuptake inhibitors. Annals of Pharmacotherapy 31, 1481-1489.
4. Conforti D, Borgherini G, Fiorellini Bernardis LA, Magni G (1999). Extrapyramidal symptoms associated with the adjunct of nortriptyline to a venlafaxine-valproic acid combination. International Clinical Psychopharmacology 14, 197-198.
5. Diler RS, Yolga A, Avci A (2002). Fluoxetine induced extrapyramidal symptoms in an adolescent: a case report. Swiss Medical Weekly 132, 125-126.
6. Figueroa Y, Rosenberg DR, Birmaher B, Keshavan MS (1998). Combination treatment with clomipramine and selective serotonin reuptake inhibitors for obsessive-compulsive disorder in children and adolescents. Journal of Child and Adolescent Psychopharmacology 8, 61-67.
7. Findling RL, McNamara NK, Gracious BL (2003). Antipsychotic agents: traditional and atypical. In: Martin A, Scahill L, Charney DS, Lecman JF (Eds.), Pediatric Psychopharmacology (pp. 328-340). New York: Oxford University Press.
8. Gill H, DeVane CL, Risch SC (1997). Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypothesis. Journal of Clinical Psychopharmacology 17, 377-399.
9. Gundersen K, Geller B (2003). Antidepressants II : tricyclic agents. In: Martin A, Scahill L, Charney DS, Lecman JF (Eds.), Pediatric Psychopharmacology (pp. 284-294). New York: Oxford University Press.
10. Hedenmalm K, Guzey C, Dahl ML, Yue QY, Spigset O (2006). Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms. Journal of Clinical Psychopharmacology 26, 192-197.
11. Horrigan JP, Barnhill LJ (1994). Paroxetine-pimozide drug interaction. Journal of the American Academy of Child and Adolescent Psychiatry 33, 1060-1061.
12. Lambert MT, Trutia C, Petty F (1998). Extrapyramidal adverse effects associated with sertraline. Progress in Neuropsychopharmacology and Biological Psychiatry 22, 741-748.
13. Lane RM (1998). SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment. Journal of Psychopharmacology 12, 192-214.
14. Leo RJ (1996). Movement disorders associated with the serotonin selective reuptake inhibitors. Journal of Clinical Psychiatry 57, 449-454.
15. Mamo DC, Sweet RA, Mulsant BH, Pollock BG, Miller MD, Stack JA (2000). Effect of nortriptyline and paroxetine on extrapyramidal signs and symptoms: a prospective double-blind study in depressed elderly patients. American Journal of Geriatric Psychiatry 8, 226-231.
16. Masmoudi K, Gras-Champel V, Bonnet I, Pannier M, Masson H, Rosa A (2000). Dementia and extrapyramidal problems caused by long-term valproic acid. Therapie 55, 629-634.
17. Oesterheld JR, Flockhart DA (2003). Pharmacokinetics II : cytochrome P459-mediated drug interactions. In: Martin A, Scahill L, Charney DS, Lecman JF (Eds.), Pediatric Psychopharmacology (pp. 54-66). New York: Oxford University Press.
18. Ozalp E, Soygur H, Cankurtaran ES, Turhal L, Cekic T, Akarsu ES, Palaoglu O, Ayhan IH (2006). Sertraline, escitalopram and tianeptine related abnormal movements but not with bupropion: a case report. Progress in Neuropsychopharmacology and Biological Psychiatry 30, 1337-1339.
19. Ricard C, Martin K, Tournier M, Begaud B, Verdoux H (2005). A case of Parkinsonian syndrome, cognitive impairment and hyperammonemia induced by divalproate sodium prescribed for bipolar disorder. Encephale 31, 98-101.
20. Sasso E, Delsoldato S, Negrotti A (1994). Reversible valproate-induced extrapyramidal disorders. Epilepsia 35, 391-393.
21. Scahill L, Martin A (2003). Pediatric psychopharmacology II general principles, specific drug treatments and clinical practice. In: Martin A, Scahill L, Charney DS, Lecman JF (Eds.), Child and Adolescent Psychiatry Text Book (pp. 951-974). New York: Oxford University Press.
22. Schillevoort I, van Puijenbroek EP, de Boer A, Roos RA, Jansen PA, Leufkens HG (2002). Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors: a case-control study using spontaneous reports. International Clinical Psychopharmacology 17, 75-79.
23. Sokolski KN, Chicz-Demet A, Demet EM (2004). Selective serotonin reuptake inhibitor-related extrapyramidal symptoms in autistic children: a case series. Journal of Child and Adolescent Psychopharmacology 14, 143-147.
24. Teoh L, Allen H, Kowalenko N (2002). Drug-induced extrapyramidal reactions. Journal of Paediatrics and Child Health 38, 95-97.
25. Winsberg BG, Kupietz SS, Yepes LE, Goldstein S (1980). Ineffectiveness of imipramine in children who fail to respond to methylphenidate. Journal of Autism and Developmental Disorders 10, 129-137.
26. Woolston J (1999). Case study, carbamazepine treatment of juvenile-onset bipolar disorder. Journal of the American Academy of Child and Adolescent Psychiatry 38, 495.